KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.99

Efficacy and Safety of Fimasartan/Indapamide Combination Therapy versus Fimasartan Monotherapy in Patients with Essential Hypertension Inadequately Responding to Fimasartan 30 mg (FINEDUO): A Randomized, Double-Blind, Multicenter, Phase III Study.

Jong-Chan Youn, So-Young Lee, Cheol Woong Yu, Ki-Chul Sung, Jinho Shin, Ju Hyeon Oh, Jin Oh Na, Dae-Hee Kim, Eun Joo Cho, Hyuck-Jun Yoon, Chan Joo Lee, Han Cheol Lee, Hae-Young Lee, Il Suk Sohn, Kyu-Sun Lee, Doo Il Kim, Woong Gil Choi, Wook-Jin Chung, Eun Mi Lee, Seung-Hyuk Choi, Seonghoon Choi, Tae Soo Kang, Sang-Hyun Ihm

Drug Des Devel Ther 20 578736

PMID42163997
PMCIDPMC13186222
DOI10.2147/DDDT.S578736
发表日期2026-05-21
入排依据:记录类型属于综述、Meta 分析、社论、评论、病例或指南。
已检查 6 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;另有 1 张未列出。
摘要

摘要

PURPOSE: Effective blood pressure (BP) control in hypertension frequently requires combination therapy, particularly in patients whose BP is inadequately controlled by monotherapy. This study evaluated the efficacy and safety of fimasartan (FMS) and indapamide (IND) sustained release (SR) combination therapy. PATIENTS AND METHODS: In this randomized, double-blind, phase III trial, patients with hypertension who remained uncontrolled after a 4-week run-in with FMS 30 mg, were randomized to FMS 30 mg/IND SR 1.5 mg or FMS 30 mg, followed by forced titration to FMS 60 mg/IND SR 1.5 mg or FMS 60 mg after 4 weeks. The primary endpoint was the change in sitting systolic BP (SiSBP) at week 8. Secondary endpoints included changes in sitting diastolic BP (SiDBP), BP control rates, response rates, and safety outcomes. RESULTS: Two hundred forty-eight patients were randomized (FMS/IND SR, n=126; FMS, n=122). At week 8, the least square mean reduction in SiSBP was greater with FMS/IND SR than with FMS (-17.9 vs -7.4 mmHg, P<0.0001). Significant improvements were also observed for SiSBP at week 4, SiDBP at week 4 and 8, and BP control rates and response rates. The safety profile was comparable between groups, with no significant differences in adverse events, including patients aged 65 years and older. CONCLUSION: FMS/IND SR combination therapy demonstrated superior antihypertensive efficacy, rapid BP control, and comparable safety to FMS monotherapy. This regimen may serve as an effective therapeutic option, particularly in elderly or high-risk hypertensive patients. CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.gov, NCT05878561.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1 Summary of patient disposition.
非 KM Figure
Figure 2Figure 2 Mean SiSBP ( A ) and SiDBP ( B ) from baseline to week 4 and 8.
非 KM Figure
Figure 3Figure 3 Blood pressure control rates ( A ) and response rates ( B ) from baseline to week 4 and 8.
非 KM Figure
Figure 4Figure 4 Blood pressure control rates < 140/90 mmHg ( A ) and control rates < 130/80 mmHg ( B ) regardless of comorbidities from baseline to week 4 and 8.
非 KM Figure
Figure 5Figure 5 Forest plot of subgroup analyses for comparison of FMS/IND combination therapy and FMS monotherapy of the changes in SiSBP from baseline to week 8.
非 KM Figure